A study has revealed that fondaparinux, a synthetic inhibitor of coagulation factor Xa, is a promising treatment option for patients with acute coronary syndromes. Mehta et al. performed a ...

Recent data have shown that fondaparinux, a selective factor Xa inhibitor, is noninferior to enoxaparin for short-term prevention of adverse cardiovascular outcomes in patients with non-ST-segment ...

Equivalent placebo boluses and injections were used in the fondaparinux group. In order to maintain blinding, a central computer system produced either real or sham activated partial ...

c If neuraxial catheter was used postoperatively, it was removed 2 or more hours before first injection of fondaparinux. d Fondaparinux could be administered 12 ± 2 hours preoperatively if ...